Logo Image
|Articles|June 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2001
  • Volume 0
  • Issue 0

Rx-to-OTC: Unwanted Attention

Author(s)Kevin Gopal

Washington, DC-An FDA advisory committee voted overwhelmingly to recommend that Claritin (loratadine), Allegra (fexofenadine), and Zyrtec (cetirizine) be changed from prescription to over-the-counter products. Although the vote is not binding, FDA usually follows such panels’ recommendations.

Articles in this issue

over 25 years ago

Industry Under Investigation

over 25 years ago

Emotion - The New Brand Integrator

over 25 years ago

For Love of the Game

over 25 years ago

Field of Dreams

over 25 years ago

Workshop: Access Options

over 25 years ago

Emotion - The New Brand Integrator

over 25 years ago

Emotion - Biotech Renaissance Man

over 25 years ago

Relocation: Coming to America

over 25 years ago

Stocks: Catching the Market Blues

over 25 years ago

Gathering Light

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more